Biohaven Ltd. (BHVN)
D
Pipeline Grade
Financial Position (from SEC Filings)
$277.1M
Cash & Equivalents
$149.9M
Quarterly Burn Rate
6 mo
Est. Cash Runway
$2,341M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-01 | Phase2 Readout | — |
| 2026-10-01 | Phase3 Readout | — |
| 2026-11-01 | Phase1 Readout | — |
| 2026-12-01 | Phase3 Readout | — |
| 2027-07-01 | Phase1 Readout | — |
Active Clinical Trials (12)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06419322 | Acceptability, Feasibility, Safety and Efficacy of a Optimized Rehabilitation Program for Treated Patients With Spinal M... | OTHER | Active Not Recruiting | 14 |
| NCT06529146 | Real-World Data Study of Troriluzole-Treated Patients With Spinocerebellar Ataxia (SCA) Compared to a Matched Natural Hi... | OTHER | Active Not Recruiting | 909 |
| NCT06309966 | Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | PHASE3 | Active Not Recruiting | 390 |
| NCT06976268 | A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson'... | PHASE3 | Recruiting | 550 |
| NCT06132893 | A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | PHASE3 | Recruiting | 390 |
| NCT07661056 | Study to Determine if BHV-1300 is Effective and Safe in Adults With Graves' Disease | PHASE3 | Recruiting | 300 |
| NCT07281495 | Taldefgrobep Alfa in Adults With Overweight and Obesity | PHASE2 | Active Not Recruiting | 150 |
| NCT06384807 | A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | PHASE2 | Recruiting | 500 |
| NCT06980649 | Study of BHV-1300 in Graves' Disease | PHASE1 | Recruiting | 15 |
| NCT07262268 | A Phase 1b Study of BHV-7000 in Participants With Inherited Erythromelalgia | PHASE1 | Enrolling By Invitation | 5 |
| NCT06874335 | A Phase 1 Study of BHV-1530 in Advanced Solid Tumors | PHASE1 | Recruiting | 140 |
| NCT07054684 | Study of BHV-1400 in IgA Nephropathy | PHASE1 | Recruiting | 20 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.
FDA-Related SEC Filings
| Date | Type | Description | Link |
|---|---|---|---|
| 2026-05-27 | 8-K | Biohaven Ltd. (BHVN) (CIK 0001935979) - EX-99.2 | EDGAR |